Summary
Recent clinical trials carried out in patients with advanced cancer have shown that recombinant TRAIL administration is usually safe and well tolerated when used either alone or in association with chemotherapeutic drugs. Notably, anticancer chemotherapy can be associated to cardiomiopathy. We have here demonstrated that TRAIL (administrated as either recombinant soluble TRAIL or as AAV-TRAIL expression viral vector) reduced the development of cardiomyopathy in the ApoE-/- diabetic mouse model. These data suggest, for the first time, that therapeutically administration of TRAIL might have a cardioprotective effect.
This is a preview of subscription content, log in via an institution to check access.
References
Herbst RS, Eckhardt SG, Kurzrock R et al (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839–2846
Soria JC, Smit E, Khayat D et al (2010) Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28:1527–1533
Secchiero P, Zauli G (2008) TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol 15:42–48
Secchiero P, Corallini F, Ceconi C et al (2009) Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PloS One 4:e-4442
Niessner A, Hohensinner PJ, Rychli K et al (2009) Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 30:789–796
Mori K, Ikari Y, Jono S et al (2010) Association of serum TRAIL level with coronary artery disease. Thromb Res 125:322–325
Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331–340
Secchiero P, Corallini F, Beltrami PA et al (2010) An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 210:274–277
Secchiero P, Candido R, Corallini F et al (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522–1530
Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126–135
Lipshultz SE, Scully RE, Lipsitz SR et al (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950–961
Fabris B, Candido R, Bortoletto M et al (2007) Dose and time-dependent apoptotic effects by angiotensin II infusion on left ventricular cardiomyocites. J Hypertens 25:1481–1490
Candido R, Forbes JM, Thomas MC et al (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785–792
Secchiero P, Zerbinati C, Rimondi E et al (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965–1974
Acknowledgments
This work was supported by a grant from “Programma di Ricerca Regione-Università 2007/2009” (Regione Emilia Romagna to P.S.) and from “Ministero dell’Università e della Ricerca Scientifica e Tecnologica” of Italy (to B.F.).
Author information
Authors and Affiliations
Corresponding author
Additional information
Barbara Toffoli and Stella Bernardi are equally contributed to this work
Rights and permissions
About this article
Cite this article
Toffoli, B., Bernardi, S., Candido, R. et al. TRAIL shows potential cardioprotective activity. Invest New Drugs 30, 1257–1260 (2012). https://doi.org/10.1007/s10637-010-9627-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9627-8